Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors.
Hepatocyte growth factor/Scatter Factor (HGF/SF) mediated stimulation of the Met receptor tyrosine kinase results in pleiotropic cellular effects including proliferation, morphogenesis, motility and invasion. In vivo, HGF/SF-Met activation has been shown to participate in tumorigenesis, angiogenesis and metastasis. Coupled with accumulating evidence that aberrant HGF/SF-Met expression is frequently observed in a variety of human tumors, often in association with progressive disease, these data present HGF/SF-Met as an attractive target for therapeutic intervention in human cancer. In this review, we will present the most compelling evidence suggesting a key role for HGF/SF-Met signaling in tumorigenesis, and discuss several possible therapeutic strategies.
Haddad
R
R
Laboratory of Tumor Metastasis and Angiogenesis, Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Lipson
K E
KE
Webb
C P
CP
D000818:Animals; D017228:Hepatocyte Growth Factor / Q000037:antagonists & inhibitors* / Q000096:biosynthesis* / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D017228:Hepatocyte Growth Factor